摘要
目的:研究麝香保心丸对急性心肌梗死(AMI)经皮冠状动脉介入治疗(PCI)患者N氨基末端钠肽前体(NT-proBNP)水平的影响。方法:为AMI在入院24h内或急诊直接接受PCI治疗的患者72例,随机分为麝香保心丸组(37例)及对照组(35例),两组患者均接受急性心肌梗死常规治疗,麝香保心丸组于入院后给麝香保心丸2粒/次,3次/d,对照组不给予。观察两组患者PCI术前、术后24 h、第10d、第6个月的NT-proBNP水平。结果:PCI术后24h、第10d及6个月麝香保心丸组患者NT-proBNP水平低于对照组,两组之间差异有统计学意义(P<0.05)。结论:麝香保心丸可降低择期PCI的AMI患者NT-proBNP水平,可使AMI患者进一步获益,减少术后再次发生心血管疾病的危险。
Objective：To investigate the effects of Shexiang Baoxin pill on N-terminal pro-B-type natriuretic peptide （NT-proBNP） of acute myocardial infarction （AMI） patients undergoing selective percutaneous coronary intervention （PCI）. Methods：72 patients with AMI undergoing PCI within 24 hours after admission or in emergency were enrolled. All patients were randomly divided into Shexiang Baoxin pill-treated group （37 cases） and control group （35 cases）. The patients in the two groups were all received the conventional treatment of AMI. The Shexiang Baoxin pill-treated group treated with Shexiang Baoxin pills 2 pills tid since admission, while control group was not given. NT-proBNP in blood of the patients in both groups was measured before PCI and 24 hours, 10 days and 6 months after PCI. Results：The plasma BNP level in Shexiang Baoxin pill-treated group was significantly lower than that in control group at 24h, 10 days and 6 months after PCI （P〈0.05）. Conclusion： Shexiang Baoxin pill can decrease the plasma BNP level in AMI patients with selective PCI. Such patients could gain further benefits by combining application of Shexiang Baoxin pill.
出处
《中医临床研究》
2013年第18期19-21,共3页
Clinical Journal Of Chinese Medicine
关键词
麝香保心丸
急性心肌梗死
经皮冠脉介入治疗
脑钠肽
Shexiang Baoxin pill
AMI
Percutaneous coronary intervention
B-type natriuretic peptide
